USA flag logo/image

An Official Website of the United States Government

Zebrafish Lipid Metabolism Assay for Drug Screening

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
66398
Program Year/Program:
2004 / SBIR
Agency Tracking Number:
DK064472
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ZYGOGEN, LLC
58 Edgewood Avenue 1st Floor, Room 122 ATLANTA, GA 30303
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2004
Title: Zebrafish Lipid Metabolism Assay for Drug Screening
Agency: HHS
Contract: 2R44DK064472-02
Award Amount: $1,947,219.00
 

Abstract:

DESCRIPTION (provided by applicant): Cardiovascular disease is the number one cause of death in the United States today. High levels of cholesterol and triglycerides have been identified as major contributing factors to heart disease. Furthermore, lipid-lowering drugs such as statins and fibrates have been shown to reduce the incidence of coronary disease. Although current drugs have enjoyed some success in this area, a need remains for improved drugs with fewer side effects. The goal of this proposal is to develop a fluorescent zebrafish assay (Z-Lipotrack) to identify new drugs for lipid management. The zebrafish has many advantages to model vertebrate diseases. In particular, they process lipids through the digestive system in a manner similar to mammals. Because zebrafish larvae are essentially transparent, such processing can be readily observed in the whole organism, with the aid of fluorescent lipid substrates, which are swallowed by the zebrafish larvae and transported from the intestine to the liver and gall bladder. To increase the usefulness of Z-Lipotrack for high throughput drug screening, a fluorescent plate reader will be developed to automatically image the Z-Lipotrack assay. Secondly, the use of Z-Lipotrack for compound optimization will be evaluated. Finally, compounds identified as potential lipid-lowering drugs in Phase 1will be fully characterized and optimized through the use of medicinal chemistry to identify lead compounds for further animal and human studies.

Principal Investigator:

Amy L. Rubinstein
4045237309
AMY@ZYGOGEN.COM

Business Contact:

Nina Sawczuk
4045237309
NINA@ZYGOGEN.COM
Small Business Information at Submission:

ZYGOGEN, LLC
ZYGOGEN, LLC KELL HALL 520 ATLANTA, GA 30303

EIN/Tax ID: 582484200
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No